tiprankstipranks
Trending News
More News >
CVRx (CVRX)
NASDAQ:CVRX
US Market
Advertisement

CVRx (CVRX) AI Stock Analysis

Compare
191 Followers

Top Page

CVRX

CVRx

(NASDAQ:CVRX)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
$7.00
▼(-6.17% Downside)
CVRx's overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. The technical analysis indicates a lack of strong momentum, while the valuation is negatively impacted by the company's unprofitability. The earnings call provides some positive outlook with revenue growth and strategic improvements, but concerns remain over rising expenses and net loss.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion.
Reimbursement Improvements
Improved reimbursement strategies enhance revenue predictability and support the adoption of CVRx's technology, strengthening market position.
Expansion of Implanting Centers
Expanding implanting centers boosts market penetration and accessibility, driving future growth and reinforcing competitive advantage.
Negative Factors
Net Loss
Ongoing net losses highlight challenges in achieving profitability, which may impact long-term financial sustainability and investment capacity.
SG&A Expenses Increase
Rising SG&A expenses can strain margins and reduce operational efficiency, potentially hindering profitability improvements over time.
Cash Flow Challenges
Negative cash flows indicate liquidity issues, limiting the company's ability to invest in growth initiatives and manage financial obligations.

CVRx (CVRX) vs. SPDR S&P 500 ETF (SPY)

CVRx Business Overview & Revenue Model

Company DescriptionCVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
How the Company Makes MoneyCVRx generates revenue primarily through the sale of its Barostim Therapy systems and related products, which are sold to hospitals and healthcare providers. The company has established key partnerships with medical institutions and health systems to promote the adoption of its technology. Additionally, CVRx benefits from reimbursements from healthcare payers for the procedures involving its devices, which is a significant revenue stream. The company may also engage in clinical studies and collaborations that can lead to new product developments, further enhancing its revenue potential.

CVRx Earnings Call Summary

Earnings Call Date:Aug 04, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Positive
The earnings call presents a generally positive outlook with significant revenue growth and expansion in implanting centers and sales territories. Improvements in reimbursement strategies and stable gross margins further contribute to the positive sentiment. However, challenges such as increased net loss, higher SG&A expenses, and rising interest expenses present areas of concern.
Q2-2025 Updates
Positive Updates
Revenue Growth
Total revenue for Q2 2025 was $13.6 million, marking a 15% increase over the same quarter last year. U.S. heart failure revenue was $12.2 million, demonstrating continued growth in the U.S. heart failure business.
Expansion of Implanting Centers
The number of active implanting centers in the U.S. increased to 240 as of June 30, 2025, up from 227 at the end of Q1 2025.
Sales Force Transformation Progress
Sales territories in the U.S. increased to 47, with significant progress in the sales force transformation. More than 35% of territory managers were hired since January 1, and over half of the area sales directors have joined in the last 12 months.
Reimbursement Improvements
CMS proposed maintaining Barostim's assignment to new technology APC 1580 with approximately $45,000 payment for outpatient procedures. Transition to Category 1 CPT codes in January 2026 is expected to improve reimbursement predictability.
Gross Margin Stability
Gross margin remained stable at 84% for Q2 2025, consistent with the prior year period.
Increased European Revenue
Revenue generated in Europe was $1.3 million for Q2 2025, a 19% increase over the prior year period.
Negative Updates
Net Loss
Net loss was $14.7 million or $0.57 per share for Q2 2025, compared to a net loss of $14 million or $0.65 per share for the prior year period.
SG&A Expenses Increase
SG&A expenses increased by $2.2 million or 11% to $23.4 million for Q2 2025, driven by higher compensation, travel, and noncash stock-based compensation expenses.
Interest Expense Rise
Interest expense increased by $0.5 million for Q2 2025 due to higher levels of borrowings under the term loan agreement.
Company Guidance
In the CVRx Q2 2025 earnings call, the company provided financial guidance, predicting total revenue for the full year 2025 to be between $55 million and $57 million, with gross margins expected to remain steady between 83% and 84%. The company also projected operating expenses to range from $96 million to $98 million. For the third quarter of 2025, CVRx anticipates revenue to fall between $13.7 million and $14.7 million. The call highlighted the company's progress in expanding its sales force, which now includes more than 35% of territory managers hired since January, and the addition of 13 new active implanting centers in the U.S., bringing the total to 240. CVRx also announced significant reimbursement advancements, including CMS proposing to maintain Barostim's assignment to new technology APC 1580, and the anticipated transition to Category 1 CPT codes in January 2026, which is expected to improve reimbursement predictability and physician payment consistency. Additionally, the company emphasized its strategic focus on developing sustainable Barostim programs and enhancing clinical evidence to support Barostim's adoption as a standard of care in heart failure treatment.

CVRx Financial Statement Overview

Summary
CVRx shows revenue growth and a strong gross profit margin, but faces profitability challenges with negative net income and EBIT margins. The balance sheet is stable with a moderate debt-to-equity ratio, yet negative return on equity reflects ongoing financial struggles. Cash flow issues persist with negative operating and free cash flows, indicating potential liquidity concerns.
Income Statement
45
Neutral
CVRx has shown consistent revenue growth, with a TTM revenue growth rate of 3.37%. However, the company is currently unprofitable, with negative net profit margins and EBIT margins, indicating challenges in achieving operational efficiency. The gross profit margin remains strong at 84%, suggesting effective cost management at the production level.
Balance Sheet
50
Neutral
The balance sheet shows a moderate debt-to-equity ratio of 0.87, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is healthy, suggesting a solid capital structure despite the negative profitability.
Cash Flow
40
Negative
Cash flow analysis reveals negative operating and free cash flows, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow is closely aligned with net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue54.65M51.29M39.30M22.47M13.04M6.05M
Gross Profit45.93M42.96M33.04M17.47M9.40M4.61M
EBITDA-46.15M-54.89M-38.73M-40.74M-40.60M-11.48M
Net Income-52.25M-59.97M-41.20M-41.43M-43.08M-14.11M
Balance Sheet
Total Assets119.56M133.41M115.23M124.94M152.55M64.78M
Cash, Cash Equivalents and Short-Term Investments95.03M105.93M90.57M106.19M142.07M59.11M
Total Debt50.54M50.43M30.61M7.09M0.0019.28M
Total Liabilities61.63M62.36M39.28M15.76M6.59M358.01M
Stockholders Equity57.93M71.06M75.95M109.18M145.96M-293.24M
Cash Flow
Free Cash Flow-39.43M-40.51M-39.61M-43.36M-28.91M-16.41M
Operating Cash Flow-39.12M-39.14M-39.02M-42.68M-27.73M-16.10M
Investing Cash Flow-306.00K-1.36M-591.00K-685.00K-1.18M-311.00K
Financing Cash Flow64.04M55.87M23.98M7.49M111.88M49.78M

CVRx Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price7.46
Price Trends
50DMA
7.66
Negative
100DMA
7.05
Positive
200DMA
9.80
Negative
Market Momentum
MACD
-0.06
Positive
RSI
49.62
Neutral
STOCH
53.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVRX, the sentiment is Neutral. The current price of 7.46 is below the 20-day moving average (MA) of 7.59, below the 50-day MA of 7.66, and below the 200-day MA of 9.80, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 49.62 is Neutral, neither overbought nor oversold. The STOCH value of 53.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVRX.

CVRx Risk Analysis

CVRx disclosed 54 risk factors in its most recent earnings report. CVRx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CVRx Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
289.32M51.384.69%27.22%695.07%
60
Neutral
272.81M-3.53-12.39%14.65%-86.36%
48
Neutral
$196.92M-92.33%23.11%18.06%
48
Neutral
241.36M-4.11128.34%45.50%53.07%
44
Neutral
39.31M-4.58-25.02%93.07%13.25%
41
Neutral
144.89M-2.88532.08%29.34%-283.53%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CVRX
CVRx
7.46
-1.47
-16.46%
MYO
Myomo
1.04
-2.78
-72.77%
BWAY
Brainsway
14.91
6.65
80.51%
LNSR
LENSAR
12.14
7.71
174.04%
MASS
908 Devices
7.56
4.11
119.13%
TLSI
TriSalus Life Sciences
4.84
0.83
20.70%

CVRx Corporate Events

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
CVRx Appoints Brent Binkowski as New COO
Positive
Aug 4, 2025

On August 4, 2025, CVRx announced the appointment of Brent Binkowski as Chief Operating Officer, effective August 11, 2025. Binkowski brings over 20 years of experience in medical devices, which is expected to enhance CVRx’s operations. The company reported a 15% increase in total revenue for the second quarter of 2025, reaching $13.6 million, driven by growth in the U.S. heart failure market. The number of active implanting centers in the U.S. grew by 27% since June 2024. CVRx is also benefiting from favorable CMS proposals for Barostim reimbursement, positioning the company for continued growth.

The most recent analyst rating on (CVRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 23, 2025